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Abstract
Background: Seasonal affective disorder (SAD) episodes will recur annually without effective intervention. Effectiveness of such
interventions is traditionally measured with depression-specific tools (e.g., Beck Depression Inventory 2nd Edition; BDI-II). In a
climate of potentially scarce resources, generic outcomes, such as Quality Adjusted Life Years (QALYs), are recommended for
cost-effectiveness research. For treatments to be deemed cost-effective, they must show effectiveness relative to each other and
relative to interventions across other disorders. To date, QALYs have not been used to determine effectiveness of SAD treatments.
Given the recurrent nature of SAD, QALYs, which weight quality of life with time, are an ideal SAD treatment outcome.
Method: A method to assess QALYs for SAD was developed using pilot clinical trial data. The method estimated health utilities, a
measure of quality of life for a QALY, by anchoring pilot BDI-II data from the SAD clinical trial with previously derived health
utilities for nonseasonal depression.
Results: Relative to no treatment, median QALYs gained ranged from 0.11–0.18 over 1 year, depending on the intervention
assessed. Discussion: Any treatment for SAD must compete with spontaneous spring remission, as illness severity attenuates in the
spring.
Limitations: Health utilities were estimated from the depression literature, and potential side effects from SAD treatments were not
included in the estimates. The clinical trial time horizon was limited to 1-year.
Conclusions: The proposed method offers researchers a tool to transform SAD efficacy data into a generic outcome for use in costeffectiveness analysis of SAD treatments.
© 2006 Elsevier B.V. All rights reserved.
Keywords: Quality adjusted life year; Cost-effectiveness; Depression; Seasonal affective disorder; Health utility

1. Introduction
1.1. Seasonal affective disorder and quality adjusted
life years
⁎ Corresponding author. Now at the Deployment Health Clinical
Center, Walter Reed Army Medical Center, Washington, DC, United
States. Tel.: +1 202 494 1392; fax: +1 202 356 1090.
E-mail address: mc_freed@onebox.com (M.C. Freed).
1
Now at the Department of Psychology, University of Vermont,
Burlington, Vermont, United States.

Seasonal affective disorder (SAD) is defined by DSMIV-TR (APA 2000) as a recurrent pattern of major depressive episodes with a temporal relationship between
the episodes and time of year. SAD affects up to 9.7% of
the population (Birtwistle and Martin, 1999; Rosen et al.,
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1990) and prevalence increases with latitude in the United
States (Mersch et al., 1999). Left untreated, SAD episodes
recur annually (Sakamoto et al., 1995). Although light
therapy (LT; Terman et al., 1989) and group cognitive
behavioral therapy (CBT; Rohan et al., 2004) improve
SAD symptoms, the outcomes used to demonstrate improvement are depression-specific. That is, measures such
as the Beck Depression Inventory, 2nd Edition (BDI-II;
Beck et al., 1996) can be used only to compare the
effectiveness of interventions for depression. In a climate
of potentially scarce resources, effective interventions
must also be cost-effective (Yates, 1994). A more generic
outcome is needed to compare the cost-effectiveness
of depression-related interventions against the effectiveness of interventions for other disorders (Pyne et al.,
2003).
The U.S. Public Health Service panel on cost-effectiveness recommended the use of quality adjusted life
years (QALYs) as that generic measure of effectiveness
to inform healthcare resource allocation decisions (Gold
et al., 1996). A QALY measures the health impact of an
intervention by capturing quality (morbidity) and length
of life (mortality) in a single dimension (Torrance and
Feeny, 1989; Weinstein and Stason, 1977). Quality of
life is weighted by time such that a year in perfect health
is worth 1 QALY and death is worth 0. QALYs can be
used to assess treatment outcomes in terms of absolute outcomes, without consideration of pre-treatment
health. Alternatively, QALYs can be used to assess
what is gained (the incremental effectiveness) over and
above no treatment (the so-called, do-nothing approach) or over and above an existing treatment. For
example, if the QALY for a usual care intervention is
0.3 and the QALY for an enhanced care intervention is
0.9, then the difference between usual care and enhanced care, 0.6, is the QALY gained (QALYG). Thus,
0.6 QALYs are gained from implementing enhanced
care over usual care.
In a review of the cost-effectiveness literature for
nonseasonal depression treatment, Barrett et al. (2005)
reported that only 12 of the 58 articles reviewed (21%)
assessed cost per QALY, a cost-utility analysis. The
recurrent nature of SAD makes QALYs an attractive
treatment outcome. Unlike other chronic conditions,
SAD remits in the spring and summer (DSM-IV-TR,
2000) for many sufferers, and thus, even without any
treatment, the change of seasons attenuates SAD
symptoms. QALYs weight quality of life with time,
and therefore can account for seasonal changes in
symptom severity. SAD treatments must compete with
these seasonal changes. However, no literature to date
reported QALYs for SAD.

1.2. Estimating health utilities
The quality of life component of a QALY can be
measured by units called health utilities, although other
similar units (generically called preference scores) of
quality of life exist. Health utilities are ratings of outcome
desirability in the face of uncertainty, where outcomes are
specific health conditions, like severe depression (Drummond et al., 1997; Torrance and Feeny, 1989). Multiple
health conditions (e.g., mild depression and severe
depression) are then rated relative to each other and
anchored by perfect health (equal to 1) and death (equal to
0). Utilities are elicited through a time consuming method
called the standard gamble (SG; Drummond et al., 1997).
Because administering the SG is not always feasible,
researchers have relied on previously published utilities.
For example, Lave et al. (1998) and Katon et al. (2005)
used the average of six published depression-related utilities scores. Participants considered depressed (via the
researchers' depression outcome) were assigned a utility
of 0.51 and participants considered not depressed were
assigned a utility of 1. Raw scores from the depressionspecific measure were linearly interpolated to reflect utilities between 0.51 and 1.0. However, the utilities that
Lave et al. (1998) and Katon et al. (2005) averaged were
not all elicited from patients with depression. Utilities
derived from patients (vs. providers or nonpatients)
are preferred (Hlatk, 1995; Montgomery and Fahey,
2001).
For clinical untreated depression, researchers have
elicited utilities as low as 0.3 from participants diagnosed
with depression (Revicki and Wood, 1998). That is,
participants were indifferent between the following two
choices: choice 1) being severely depressed and choice
2) receiving a depression-curing intervention with the
probability of success being 0.3 and death 0.7. The
probability of success at the point of indifference is the
health utility. Utilities for conditions such as treated
remitted depression with no pharmacological treatment
are 0.895 (Revicki et al., 1995; Revicki et al., 1997) and
0.86 (Revicki and Wood, 1998). Revicki and Wood
(1998) also elicited utilities from depressed participants for mild depression (0.64–0.73) and moderate
depression (0.55–0.63). However, the mild and moderate depression conditions included the experience
of medication side effects along with symptoms of
depression.
1.3. Study aims
We present a method to capture QALYs and QALYGs
for patients with SAD using Revicki and Wood's (1998)
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patient-elicited utility anchors and raw scores from the
BDI-II (Beck et al., 1996). We demonstrate our method
using pilot data from a clinical trial examining treatments
for SAD. As described earlier, a paucity of research
exists on QALYs for depression, and no research exists
on QALYs for SAD.
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but BDI-II scores were significantly more favorable for
participants in CBT and CBT + LT, when compared to
LT at the one-year winter follow up.
3. Results
3.1. Health utility estimation

2. Method
Data from 20 participants residing in the greater
Washington DC area who had enrolled in and completed
a pilot investigation examining the efficacy of a novel
SAD-tailored cognitive–behavioral therapy (CBT) for
patients with SAD were used. Participants entered treatment once they met Structured Interview Guide for the
Hamilton Depression Rating Scale–Seasonal Affective
Disorder Version (SIGH–SAD; Williams et al., 1992)
criteria for a SAD episode. In a 3-condition design with
3 repeated measures, participants were randomized to 1)
CBT alone (12, group sessions each 1.5 h long held
twice weekly for 6 weeks), 2) Light Therapy alone (LT;
10,000-lux standard light box viewed in participants'
homes in 45-minute doses, twice daily for 6 weeks), or
3) CBT + LT (all elements of CBT and LT concurrently).
Each participant completed the SIGH-SAD and BDI-II
at pre-treatment, immediate post-treatment, and oneyear following the end of treatment. The two outcome
measures used in study were the SIGH-SAD (Williams et al., 1992) and the BDI-II (Beck et al., 1996.)
Both measures have been used extensively in depression research and have adequate reliability and
validity.
Institutional Review Boards of the authors' affiliated
universities approved the current project. The pilot data
showing the efficacy of CBT for SAD can be found in
Rohan et al. (2004). To summarize, Rohan et al. found
no difference among the conditions at post-treatment,

For the purposes of estimating health utilities, a BDIII conversion method was developed with consultation
from Dr. Scott Parker (personal communication, 2004).
In order to convert BDI-II scores to the estimated health
utilities, BDI-II scores of 63 (indicating maximal severe
depression) were matched to the published health utility
for untreated depression (0.3; Revicki and Wood, 1998).
Then, BDI-II scores of 0 (indicating no depression) were
matched to the published health utility for depression in
remission, not in treatment (0.9; Revicki et al., 1995;
Revicki and Wood, 1998; rounded to the nearest 10th).
Between these published anchors, equally spaced estimated health utility ranges were determined for each
level of depression severity as demarcated by BDI-II
scores. (Of note, Beck et al., 1996, derived optimal cut
scores using receiver operating characteristic (ROC)
curves to determine ordinal levels of depression severity.) This was accomplished by dividing the difference
between the maximum health utility of 0.9 and minimum
utility of 0.3 (difference equal to 0.6) by 5, the number of
severity ranges on the BDI-II: remission, sub-clinical,
mild, moderate, and severe. Therefore, range of each
severity level was determined to be 0.12 health utility
units. The conversion method and the resulting transformation tool can be seen in Table 1 and Fig. 1. The
estimated health utilities were assigned to each participant at pre-treatment, post-treatment, and 1-year followup. The estimated health utilities for nonseasonal
depression should be comparable to SAD because

Table 1
Health utility estimation method
Severity

BDI-II

Rationale for Health State Rating

Utility

Remission⁎

b9

0.78 to 0.9

Sub-clinical

9–13

Mild⁎
Moderate⁎
Severe⁎

14–19
20–28
29–63

Revicki et al. (1995) and Revicki et al. (1997) used utilities of 0.895
and 0.89, respectively. Revicki and Wood (1998) elicited utilities from patients of 0.86.
Not an official BDI-II category; however, participants were still symptomatic.
These utilities were estimated.
No published utilities exist for this severity. Health utilities were therefore estimated.⁎⁎
No published utilities exist for this severity. Health utilities were therefore estimated.⁎⁎
Revicki et al. (1995) and Revicki et al. (1997) used utilities of .31 and .306, respectively,
for untreated depression. Revicki and Wood (1998) elicited 0.3 for untreated severe depression.

0.66 to b0.78
0.54 to b0.66
0.42 to b0.54
0.3 to b0.42

⁎BDI-II ranges from Beck et al. (1996).
⁎⁎Revicki and Wood (1998) elicited utilities ranging from 0.64–0.73 for mild depression and 0.55–0.63 for moderate depression. However, their
health state descriptions included side effects from pharmacological interventions.
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Fig. 1. BDI-II scores to health utilities transformation tool.

SAD is regarded as a seasonal subtype of Major Depression (DSM-IV-TR, 2000).
3.2. QALYs and QALYGs in SAD
To establish QALYs and QALYGs for patients with
SAD, the estimated utilities were weighted by time and
then summed over 1 year. This time weighting process
helped account for the fact that individuals with SAD do
not experience equal symptom severity throughout the
entire year. By definition, individuals with SAD experience the most severe symptoms during the three
winter months, with milder symptom profiles occurring
during fall and spring months. In a given year, a single
health utility cannot be representative of overall health
status.
In consultation with a recognized SAD expert (Dr.
Kelly Rohan, personal communication, 2004), a method
was created to best fit the pre-treatment, post-treatment,

and 1-year follow-up data into a one-year course of SAD
(Table 2). Pre-treatment BDI-II scores were used to
estimate health utilities for the 1.5 months (i.e., 6 weeks)
of treatment (January 1st to mid-February). Assuming that
SAD patients were symptomatic until mid-May, posttreatment scores were used to estimate health utilities for
next 3 months. The expected spontaneous and complete
remission period from mid-May through the end of
September was assigned the most favorable utility 0.9).
Because SAD symptoms begin in the early fall, 1-year
follow-up scores were used to estimate utilities for the
remaining 3 months of the year (i.e., from early October
through December). Thus, a QALY over 1 year was
calculated by weighting time with a) the median pretreatment estimated utilities (pre), b) post-treatment
estimated utilities (post), c) one-year follow-up estimated
utilities (1-year) and d) spring and summer (spr sum)
estimated remission. The following formula was used:
½ðpre  1:5 monthsÞ þ ðpost  3 monthsÞ þ ð0:9 spr sum  4:5 monthsÞ þ ð1  year  3 monthsÞ
12 months

ð1Þ

The calculations assumed no change in symptom
severity across the 6-week treatment phase and that any
residual SAD symptoms following treatment persisted
through mid-May. Also, the one-year follow-up data
back estimated SAD severity during the preceding
months of October through December, months where
symptoms are presumably less severe. And, the oneyear assessment occurred when SAD symptoms are the
most severe. Thus, the three month period using this
one-year data likely estimates symptom severity to be
overly severe. The natural course of SAD symptom

Table 2
QALY and QALYG calculation method
QALY method
Timeframe

Number of months

Data used

Early January to mid-February
Mid-February to mid-May
Mid-May to end of September
Beginning of October to end of December

1.5
3
4.5
3

Pre-treatment
Post-treatment
Spontaneous remission a
1-year follow-up

Timeframe

Number of months

Data used

Early January to mid-February; beginning of October to end of December
Mid-May to end of September

7.5
4.5

Pre-treatment scores
Spontaneous remission b

QALYG method
Step 1: Calculate no-treatment QALY

Step 2: Subtract no-treatment QALY from QALY
a

Assumed all participants spontaneously remit during summer.
Assumed all participants spontaneously remit during summer. Because there is no change during the summer months, nothing is gained from
receiving treatment for SAD during these months.
b

M.C. Freed et al. / Journal of Affective Disorders 100 (2007) 83–89

Fig. 2. Median SAD health utilities over 1-year.

onset, escalation, and offset is obviously more gradual
than is reflected in the formula.
Fig. 2 graphically displays the median estimated
utilities from the pilot dataset (Rohan et al., 2004). Here,
a QALY is represented as the area under the curve for a
particular treatment, and in this example, is defined as
the average monthly utility. Time is an important
dimension for a QALY, as theoretical remission during
the spring and summer lessens the overall severity
captured in a single QALY score. Median, mean, and
parenthesized standard deviations are as follows:
CBT = 0.79, 0.78, (0.03); LT = 0.73, 0.74, (0.07); and
CBT + LT = 0.80, 0.81, (0.05). The Kruskal–Wallis test
(Mehta and Patel, 2000) showed no difference in
QALYs among the treatment conditions, p = ns.
To assess QALYGs, pre-treatment utilities were substituted for post-treatment and 1-year utilities, in the
formula above, resulting in a no-treatment QALY. The
no-treatment QALY was subtracted from the treatment
QALY, resulting in a QALYG. For example, the median
QALYG for CBT is 0.18. To calculate this no-treatment
QALY, the pre-treatment CBT health utility was 0.42
(seen in Fig. 2) to represent quality of life in the symptomatic months. The median no-treatment CBT QALY,
0.60, was subtracted from the QALY for CBT, 0.78,
resulting in 0.18 QALYG. QALYGs greater than 0.12
indicated categorical improvement from a severity level
(e.g., moderate to mild depression). Median, mean, and
parenthesized standard deviations are as follows:
CBT = 0.18, 0.18, (0.06); LT = 0.11, 0.11, (0.06); and
CBT + LT = 0.14, 0.14, (0.05). The Kruskal–Wallis test
(Mehta and Patel) showed no difference in QALYGs
among the treatment conditions, p = ns.
4. Discussion
We developed a method to measure a QALY and
QALYG for individuals suffering from a subtype of
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depression: SAD. This method estimated health utilities
from BDI-II scores using published depression-related
utilities as anchors. The estimated utilities were weighted
by time and summed. The resulting outcomes, QALYs
and QALYsG, can be used to assess both clinical and
statistical significance from clinical trial data. That is,
QALYs can be analyzed statistically, but they also have
qualitative meaning. For example, a QALY of 0.9 would
indicate depression in remission. Similarly, a QALYG of
greater than 0.12 would indicate improvement from one
BDI-II-determined severity level to another. Using
QALYs allows for comparison among treatments for a
single disorder or for comparison among treatments of
differing disorders (Drummond et al., 1997). Thus,
policy and decision makers now have a common
metric, albeit constructed with pilot data, on which
to compare treatments for SAD relative to each other
or relative to treatments for other disorders (e.g., CBT
for depression relative to CBT for anxiety). Use of
the proposed transformation tool gives clinical researchers a method for generalizing disorder-specific
treatment outcomes to a wider audience. Particularly,
this wider audience may include health economists
and epidemiologists, who are involved in resource
allocation.
We recognize several limitations of the current paper.
First, we did not administer the standard gamble (SG) to
our participants. We assumed that the phenomenological
experience of being depressed from nonseasonal depression would parallel an episode of SAD. And, we assumed that the severity categories of the BDI-II would
match the severity descriptions used by the researchers
from whom we estimated our health utilities. It is not
known whether our estimated utilities preserved the
preferences inherent in the original utilities elicited from
patients diagnosed with depression. Second, we chose to
apply health utilities developed from researchers who
administered the SG to patients, even though other
methods existed. For example, Hatziandreu et al. (1994)
elicited preferences from a physician panel rather than
from actual patients.
Third, we used data from a pilot clinical trial (Rohan
et al., 2004), which was underpowered and not designed
to inform researchers about the course of SAD. The lack
of significant differences among treatments using the
QALY(G) scores may have reflected lack of power and
not lack of treatment differences, as Rohan et al., reported
significant treatment group differences at her 1-year
follow-up. The limited number of symptomatic months
for SAD patients reduced the overall QALY(G) severity,
thereby masking gains attributable to treatment. Moreover, participants were assessed three times. Symptoms of
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SAD may fluctuate between assessments (e.g., assumed
spontaneous remission during spring and summer
months), thereby impacting our calculations of QALY
(G). Fourth, QALYs are often (but not always) modeled
using Bayesian data analytic procedures (O'Hagan and
Luce, 2003), where parameters of the model are varied in
sensitivity analyses to examine possible changes on
outcomes. For example, a utility for severe depression
could range from 0.3 (Revicki and Wood, 1998) to 0.51
(Lave et al., 1998), thus impacting the overall QALY or
QALYG. Fifth, our estimate of a do-nothing approach
used within-group pre-treatment scores. Participants were
deliberately not enrolled in treatment until they met
criteria for a SAD episode. The pre-treatment scores
reflected the most severe participant scores. It is possible
that participants would experience some improvement
even without treatment, thus reducing the difference
between an actual do-nothing control and presumed
improvement from treatment. And finally, we looked at
QALY(G)s over 1 year, rather than over a participant's
lifetime, as is the typical method for assessing QALYs.
Despite these limitations, incorporating QALYs into
treatment-outcome research for SAD moves us one step
closer to completing the research agenda argued for by
Yates (1994): the assessment of both costs and outcomes
to allow for more complete theoretical and empirical
models of mental health treatment.
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